sorbitan monooleate (Span 80)

05/30/2023 - "While the addition of Span 80 reduced the mean particle size of the coating, enhanced the water resistance of the film, and helped to reduce blueberry weight loss. "

01/01/2019 - "Results & methodology: During this study, Tween 80 and Span 80 were added to EGCG at hydrophilic-lipophilic balance (HLB) values of 4.3, 6 and 8. The results showed that lowering the HLB value increases the log P value of EGCG and results in higher IC50 values in Henrietta Lacks (HeLa) cancer cells than that of EGCG. "
12/01/2021 - "It was also confirmed that the coexistence of PEG-Span 80 niosome with DOX-PEG liposome in 50% serum or in 50% supernatant of tumor tissue homogenate significantly increased DOX release from PEG liposome, suggesting that DOX release from DOX-PEG liposome within tumor tissue would be enhanced via the interaction with PEG-Span 80 niosome. "
12/01/2021 - "The sequential administration of PEG-Span 80 niosome at 24 or 48 h after dosing of DOX-PEG liposome provided a higher anti-tumor effect than the single dose of DOX-PEG liposome in the C26-bearing mice. "
04/15/2010 - "In vitro and in vivo anti-tumor effects of novel Span 80 vesicles containing immobilized Eucheuma serra agglutinin."
04/01/2015 - "Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles."

07/01/2012 - "The objective of this study was to present data on 24 of 591 dermatitis patients with reactions to SSO and/or sorbitan monooleate (SMO) on patch testing. "
09/01/2020 - "Photoallergic systemic dermatitis caused by sorbitan monooleate in craft beer."
11/01/2008 - "To present data on 13 of 112 dermatitis patients who reacted to SSO and/or sorbitan monooleate (SMO) on patch testing. "

08/04/2023 - "The synthesis and development of poly(ε-caprolactone) conjugated polyoxyethylene sorbitan oleate-based micelles for curcumin drug release: an in vitro study on breast cancer cells."

01/05/2022 - "The present study aimed to develop a method for LLC using sorbitan monooleate (LLC-SMO) instead of GDO to prepare a one-month sustained-release formulation of naltrexone (NTX) that is applied for the treatment of autism and treating alcohol dependence. "